Disease: invasive aspergillosis (IA)

ABPA in post-tuberculosis lung disease: A diagnostic pitfall or genuine entity?

mycolabadmin

This article addresses confusion between two Aspergillus lung infections that commonly occur after tuberculosis: ABPA and CPA. While they have overlapping symptoms and test results, they require different treatments—ABPA responds to short-term steroids while CPA needs prolonged antifungal drugs. Importantly, giving steroids for misdiagnosed CPA can be harmful, so doctors should be cautious about diagnosing ABPA in tuberculosis survivors and consider CPA instead.

Read More »

Genotypic and Phenotypic Investigation of Clinical Aspergillus isolates from Iran Indicates Nosocomial Transmission Events of Aspergillus flavus

mycolabadmin

Researchers studied fungal infections caused by Aspergillus species in Iranian hospitals from 2020 to 2023. They found that Aspergillus flavus was the most common cause of infection and discovered evidence of several hospital-related outbreaks through genetic analysis. All isolates tested were susceptible to current antifungal medications, but the discovery of hospital transmission suggests the need for better infection control measures like improved air filtration in hospitals.

Read More »

ABPA in post-tuberculosis lung disease: A diagnostic pitfall or genuine entity?

mycolabadmin

After tuberculosis treatment, some patients develop fungal lung infections that can look very similar to an allergic fungal disease called ABPA. This editorial warns doctors that they need to be careful about diagnosing ABPA in tuberculosis patients because treating it with the wrong medications could make the fungal infection worse. The key difference is that true ABPA causes wheezing and asthma-like symptoms, while post-TB fungal infections cause cavities and scarring in the lungs.

Read More »
Scroll to Top